IRD

3.9902.21%
GM

George Magrath

CEO & Director

Dr. George Magrath, MD, MBA, MS, serves as Chief Executive Officer & Director of Opus Genetics, Inc. (formerly known as Ocuphire Pharma, Inc.) since November 1, 2023. He was an Analyst at Edison Investment Research Limited since 2015. He covered the healthcare sector. Dr. Magrath has eight years of experience in seed and venture funding. Dr. Magrath practices ophthalmology. He has pursued training in surgery, ophthalmology and ophthalmic oncology. Dr. Magrath holds an MD and an MBA. Dr. Magrath was most recently the Chief Executive Officer of Lexitas Pharmaceutical Services, Inc., where he led the company through significant growth, broadened its business lines and increased revenue substantially. He successfully led Lexitas through the acquisition and integration process with QHP Capital, creating a premier ophthalmology contract research organization and generating significant value for investors. Prior to Lexitas, Dr. Magrath served as Medical Director to Hovione Pharmaceuticals, LLC, from 2017 until 2020, responsible for developing and advancing the companys proprietary drugs in dermatology, ophthalmology and respiratory. He has served on many industry advisory boards and has authored numerous peer-reviewed publications. He was Chief Medical Officer and Chief Executive Officer at Lexitas Pharmaceutical Services, Inc from 2020 until 2023. He was Director of Implicit Bioscience, Inc. (2022 – 2023), Line 6 Biotechnology, Inc. (2022 – 2023), Lexitas Pharmaceutical Services, Inc. (2021 – 2023). He is Director of NanoRetinal, Inc. since 2024, Voxeleron, Inc. since 2024. Dr. Magrath received his MD from the Medical University of South Carolina, M.B.A. from The Citadel - The Military College of South Carolina, M.S. in Applied Economics from Johns Hopkins University and B.S. in Biological Chemistry from Clemson University.

Positions